Resources for Patients and their Families
Request Free Guide

Mesothelioma Doctors

Steven Ades, MD

Dr. Ades
Burlington, VT

Dr. Steven Ades

Medical Oncologist

The University of Vermont Cancer Center

111 Colchester Avenue
Main Campus, Main Pavilion, Level 2

Burlington, VT 05401

Need Help Contacting This Doctor?

Dr. Steven Ades is a medical oncologist at The University of Vermont Medical Center and associate professor at the Larner College of Medicine at UVM in Burlington, Vermont. Dr. Ades has expertise in peritoneal mesothelioma, with a particular interest in radiation therapy for abdominal mesothelioma and supportive care for patients.

Dr. Ades has been involved in clinical research focusing on adjuvant therapies in multimodal treatment plans to improve patient outcomes. He has also helped research biomarkers, which could allow for earlier detection and diagnosis of many cancers, including mesothelioma. Dr. Ades has authored and co-authored over 40 articles and medical studies, which can be found in presitigious medical journals like the Journal of Clinical Oncology.

Main Specialty: Medical Oncology

Other Interests & Specialties: Mesothelioma and peritoneal mesothelioma, adrenal cancer, anal cancer, appendix cancer, bile duct cancer, bladder cancer, carcinoid tumor, carcinoma, colon cancer, esophageal cancer, gallbladder cancer, gastrointestinal cancer, genitourinary cancer, hematologic cancer, kidney cancer, liver cancer, neuroendocrine cancer, non-hodgkin’s lymphoma, oncology, pancreatic cancer, penile cancer, prostate cancer, rectal cancer, small intestine cancer, stomach cancer, testicular cancer and urethral cancer.

Certifications, Awards & Accolades: Board Member of the American Board of Internal Medicine for Internal Medicine and Board Member of American Board of Internal Medicine for Medical Oncology

Education & Experience:

Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial. Journal of Clinical Oncology. May 2018;36:15.

NKX2.2, PDX-1 and CDX-2 as potential biomarkers to differentiate well-differentiated neuroendocrine tumors. Biomarker Research. April 2018;6:15. doi: 10.1186/s40364-018-0129-8

Enhancing the Khorana Score: Traditional VTE Risk Factors Are Important in Predicting Long Term VTE Risk in Cancer Patients Initiating Chemotherapy. Blood. 2017; 130:753.

Author: Linda Molinari

Editor in Chief, Mesothelioma Cancer Alliance

Linda Molinari

Reviewer: Annette Charlevois

Patient Support Coordinator

Annette Charlevois
Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: